Cargando…
Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
A growing body of literature links events associated with the progression and severity of immunity and inflammatory disease with the composition of the tissue extracellular matrix as defined by the matrisome. One protein in the matrisome that is common to many inflammatory diseases is the large prot...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435723/ https://www.ncbi.nlm.nih.gov/pubmed/34527586 http://dx.doi.org/10.3389/fonc.2021.712807 |
_version_ | 1783751857404903424 |
---|---|
author | Hirani, Priyanka Gauthier, Valentine Allen, Carys E. Wight, Thomas N. Pearce, Oliver M. T. |
author_facet | Hirani, Priyanka Gauthier, Valentine Allen, Carys E. Wight, Thomas N. Pearce, Oliver M. T. |
author_sort | Hirani, Priyanka |
collection | PubMed |
description | A growing body of literature links events associated with the progression and severity of immunity and inflammatory disease with the composition of the tissue extracellular matrix as defined by the matrisome. One protein in the matrisome that is common to many inflammatory diseases is the large proteoglycan versican, whose varied function is achieved through multiple isoforms and post-translational modifications of glycosaminoglycan structures. In cancer, increased levels of versican are associated with immune cell phenotype, disease prognosis and failure to respond to treatment. Whether these associations between versican expression and tumour immunity are the result of a direct role in the pathogenesis of tumours is not clear. In this review, we have focused on the role of versican in the immune response as it relates to tumour progression, with the aim of determining whether our current understanding of the immunobiology of versican warrants further study as a cancer immunotherapy target. |
format | Online Article Text |
id | pubmed-8435723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84357232021-09-14 Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer Hirani, Priyanka Gauthier, Valentine Allen, Carys E. Wight, Thomas N. Pearce, Oliver M. T. Front Oncol Oncology A growing body of literature links events associated with the progression and severity of immunity and inflammatory disease with the composition of the tissue extracellular matrix as defined by the matrisome. One protein in the matrisome that is common to many inflammatory diseases is the large proteoglycan versican, whose varied function is achieved through multiple isoforms and post-translational modifications of glycosaminoglycan structures. In cancer, increased levels of versican are associated with immune cell phenotype, disease prognosis and failure to respond to treatment. Whether these associations between versican expression and tumour immunity are the result of a direct role in the pathogenesis of tumours is not clear. In this review, we have focused on the role of versican in the immune response as it relates to tumour progression, with the aim of determining whether our current understanding of the immunobiology of versican warrants further study as a cancer immunotherapy target. Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435723/ /pubmed/34527586 http://dx.doi.org/10.3389/fonc.2021.712807 Text en Copyright © 2021 Hirani, Gauthier, Allen, Wight and Pearce https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Hirani, Priyanka Gauthier, Valentine Allen, Carys E. Wight, Thomas N. Pearce, Oliver M. T. Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer |
title | Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer |
title_full | Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer |
title_fullStr | Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer |
title_full_unstemmed | Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer |
title_short | Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer |
title_sort | targeting versican as a potential immunotherapeutic strategy in the treatment of cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435723/ https://www.ncbi.nlm.nih.gov/pubmed/34527586 http://dx.doi.org/10.3389/fonc.2021.712807 |
work_keys_str_mv | AT hiranipriyanka targetingversicanasapotentialimmunotherapeuticstrategyinthetreatmentofcancer AT gauthiervalentine targetingversicanasapotentialimmunotherapeuticstrategyinthetreatmentofcancer AT allencaryse targetingversicanasapotentialimmunotherapeuticstrategyinthetreatmentofcancer AT wightthomasn targetingversicanasapotentialimmunotherapeuticstrategyinthetreatmentofcancer AT pearceolivermt targetingversicanasapotentialimmunotherapeuticstrategyinthetreatmentofcancer |